Lavö B, Stenstam M, Nielsen A L
Scand J Gastroenterol Suppl. 1987;130:77-80. doi: 10.3109/00365528709091003.
The effects of loperamide in patients with IBS (all had diarrhoea as a main symptom) were studied in a double-blind placebo controlled trial. Subjective overall response stool consistency and six individual symptoms (urgency, pain, frequency, flatulence, borborygmi and painful propulsions) were studied over a 13 week long treatment period. Twenty-one patients out of 25 completed the trial, 11 in the loperamide group and 10 in the placebo group. A significant advantage for loperamide was found for stool consistency (p less than 0.001), pain (p less than 0.02) and urgency (p less than 0.05). Subjective overall response was also significantly better in the loperamide group (p less than 0.03). Self-titration of dose and administration in a single nightly dose was safe and efficient.
在一项双盲安慰剂对照试验中，研究了洛哌丁胺对肠易激综合征患者（均以腹泻为主要症状）的疗效。在为期13周的治疗期间，研究了主观总体反应、大便稠度以及六种个体症状（急迫感、疼痛、排便频率、肠胃胀气、腹鸣和疼痛性推进感）。25名患者中有21名完成了试验，洛哌丁胺组11名，安慰剂组10名。在大便稠度（p<0.001）、疼痛（p<0.02）和急迫感（p<0.05）方面，发现洛哌丁胺具有显著优势。洛哌丁胺组的主观总体反应也显著更好（p<0.03）。剂量的自我滴定以及每晚单次给药是安全有效的。
